Rituximab, Fludarabine, Mitoxantrone, Dexamethasone (R-FND) Plus Zevalin for High-Risk Follicular Lymphoma
NCT00290511
Completed
The goal of this clinical research study is to learn if chemotherapy given with rituximab, followed by Ibritumomab tiuxetan (Zevalin), and then followed by rituximab can help to control lymphoma. The safety of this treatment schedule will also be studied. Objectives: 1. To assess whether the time to progression for these high-risk patients can be prolonged to a median of 36 months, compared to the historical expectation of approximately 24 months. 2. To assess the tolerance and efficacy of Y2B... Read More
Gender:
ALL
Ages:
60 years and above
Trial Updated:
03/24/2022
Locations: University of Texas MD Anderson Cancer Center, Houston, Texas
Conditions: Lymphoma
Register for Updates
A Phase II Study of Carfilzomib in Relapsed Waldenström's Macroglobulinemia (WM) IST-CAR-531
NCT01813227
Completed
The purpose of this study is to evaluate the safety and effectiveness of an investigational study drug called carfilzomib. The investigators want to find out what effects, good and/or bad, it has on patients and their cancer if treatment continues beyond previous carfilzomib treatment study. Carfilzomib (KyprolisTM) is approved by the U.S. Food and Drug Administration (FDA) to be used only in certain U.S. patients with relapsed and refractory multiple myeloma that have tried and failed other th... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/18/2022
Locations: John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey
Conditions: Waldenstrom Macroglobulinemia
Register for Updates
Combination Study for High Risk Multiple Myeloma Patients
NCT03104270
Terminated
Despite the recent introduction of novel anti-multiple myeloma (MM) agents, high risk MM remains with poor prognosis and a therapeutic challenge. Elotuzumab (ELO) is a humanized monoclonal antibody that recognizes CS1/CD139, a molecule highly expressed in MM cells. The ELO (10 mg/kg), lenalidomide (LEN) and dexamethasone (DEX) combination achieves high overall response rates (ORR) and long progression-free survival (PFS) for patients with relapsed/refractory disease (RR) MM and those with impair... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/15/2022
Locations: California Cancer Associates for Research & Excellence (cCARE), Encinitas, California +5 locations
Conditions: Multiple Myeloma
Register for Updates
Safety and Efficacy of Isatuximab in Lymphoblastic Leukemia
NCT02999633
Terminated
Primary Objective: To evaluate the efficacy of isatuximab. Secondary Objectives: * To evaluate the safety profile of isatuximab. * To evaluate the duration of response (DOR). * To evaluate progression free survival (PFS) and overall survival (OS). * To evaluate the pharmacokinetics (PK) of isatuximab in participants with T-ALL or T-LBL. * To evaluate immunogenicity of isatuximab in participants with T-ALL or T-LBL. * To assess minimal residual disease (MRD) and correlate it with clinical outc... Read More
Gender:
ALL
Ages:
16 years and above
Trial Updated:
03/10/2022
Locations: Investigational Site Number 8400002, Atlanta, Georgia +16 locations
Conditions: T-cell Type Acute Leukemia-Precursor, T-lymphoblastic Lymphoma/Leukaemia
Register for Updates
A Clinical Study of Melphalan Flufenamide (Melflufen) and Dexamethasone for Patients With Immunoglobulin Light Chain (AL) Amyloidosis
NCT04115956
Terminated
This is a phase 1/2 open label study of melphalan flufenamide (melflufen) in combination with dexamethasone for participants with Al amyloidosis following at least one prior line of therapy. Melflufen will be administered on Day 1 of each 28-day cycle in combination with dexamethasone on days 1 and 2. In both phases, treatment of each individual participant will continue for up to 8 cycles or until any stopping events occur. Approximately 46 participants will be enrolled. The study was intend... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/10/2022
Locations: Boston University Medical Center, Boston, Massachusetts +8 locations
Conditions: AL Amyloidosis
Register for Updates
Low Dose Dexamethasone for Distal Radius Fractures
NCT05274113
Unknown
The addition of the steroid dexamethasone to a single injection of local anesthetic has been shown to significantly prolong the duration of peripheral nerve blockade compared to local anesthetic alone. This allows for improved post-operative pain scores and reduces opioid use in the early post-operative period. However, the use of a steroid adjuvant in regional nerve blocks is generally not considered standard of care, and there is considerable variation among anesthesiologists regarding preferr... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/09/2022
Locations: Rothman Orthopaedic Institute, Philadelphia, Pennsylvania
Conditions: Post Operative Pain, Distal Radius Fracture
Register for Updates
Carfilzomib and Hyper-CVAD in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoma
NCT02293109
Completed
This phase I trial studies the side effects and best dose of carfilzomib when given together with the hyperfractionated (hyper)-cyclophosphamide, vincristine sulfate, doxorubicin hydrochloride, and dexamethasone (CVAD) chemotherapy regimen in treating patients with newly diagnosed acute lymphoblastic leukemia or lymphoma. Carfilzomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as cyclophosphamide, vincristine sulfat... Read More
Gender:
ALL
Ages:
Between 18 years and 64 years
Trial Updated:
03/08/2022
Locations: University of California Davis, Sacramento, California
Conditions: Contiguous Stage II Adult Lymphoblastic Lymphoma, Noncontiguous Stage II Adult Lymphoblastic Lymphoma, Stage I Adult Lymphoblastic Lymphoma, Stage III Adult Lymphoblastic Lymphoma, Stage IV Adult Lymphoblastic Lymphoma, Untreated Adult Acute Lymphoblastic Leukemia
Register for Updates
Steroid vs. Anti-vascular Endothelial Growth Factor for Diabetic Macular Edema Prior to Phacoemulsification
NCT03832179
Unknown
The primary objective of this study is to compare the efficacy of antecedent intravitreal anti-vascular endothelial growth factor therapy vs. Ozurdex in reducing post-cataract surgery related macular edema in patients with pre-existing diabetic macular edema.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/01/2022
Locations: Bay Area Retina Associates, Walnut Creek, California
Conditions: Diabetic Macular Edema, Cataract
Register for Updates
Study Assessing AR-1105 in Subjects With Macular Edema Due to Retinal Vein Occlusion (RVO)
NCT03739593
Completed
This study will evaluate the safety, tolerability and efficacy of AR-1105 (dexamethasone implant) for the treatment of macular edema (ME) due to retinal vein occlusion (RVO). A more durable intravitreal implant containing a low dose of dexamethasone may result in less frequent retreatments, and potentially lower the incidence of steroid-related side effects without compromising efficacy.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
02/15/2022
Locations: Retinal Research Institute, LLC, Phoenix, Arizona +10 locations
Conditions: Macular Edema
Register for Updates
TUSC2-nanoparticles and Erlotinib in Stage IV Lung Cancer
NCT01455389
Terminated
The goal of phase 1 of this clinical research study is to find the highest dose of DOTAP:Chol-TUSC2 that can be safely given in combination with Tarceva (erlotinib hydrochloride) to patients with NSCLC. The goal of phase 2 of this clinical research study is to learn if the combination of DOTAP:Chol-TUSC2 and erlotinib hydrochloride can help to control NSCLC. The safety of this drug combination will also be studied in both phases. DOTAP:Chol-TUSC2 (previously FUS1) is a drug that helps transfe... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/11/2022
Locations: UT MD Anderson Cancer Center, Houston, Texas
Conditions: Lung Cancer
Register for Updates
Study of ACY-1215 in Combination With Lenalidomide, and Dexamethasone in Multiple Myeloma
NCT01583283
Completed
The purpose of this study is to determine the best dose of ACY-1215 in combination with lenalidomide and dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma. Once determined, the purpose of this study will be to determine the efficacy of ACY-1215 in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma who have had 1-3 prior therapies and who are not lenalidomide-refractory.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/07/2022
Locations: Dana Farber Cancer Institute, Boston, Massachusetts +4 locations
Conditions: Multiple Myeloma
Register for Updates
NA-831, Atazanavir and Dexamethasone Combination Therapy for the Treatment of COVID-19 Infection
NCT04452565
Unknown
This Phase 2/3 trial evaluates four treatment strategies for non-critically ill hospitalized participants (not requiring ICU admission and/or mechanical ventilation) with SARS CoV-2 infection, in which participants will receive NA-831 or Atazanavir with or without Dexamethasone.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
01/31/2022
Locations: Coronavirus Research Institute- Testing Site, Los Angeles, California +30 locations
Conditions: Coronavirus Infection, Severe Acute Respiratory Infection, Severe Acute Respiratory Syndrome Coronavirus 2
Register for Updates